Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 3 Glioblastoma 2 Upper Tract Urothelial Carcinomas 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Papillomavirus Infections 1 Oncogenic osteomalacia 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Melanoma 1 Hypophosphatemia 1 Hematologic Neoplasms 1 Glioma 1 Breast Neoplasms 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

Ipilimumab 98 pembrolizumab 84 Nivolumab 82 aldesleukin 51 Cyclophosphamide 49 Interleukin-2 38 fludarabine phosphate 31 Vemurafenib 31 Dacarbazine 31 dabrafenib 29 trametinib 28 Temozolomide 26 fludarabine 25 CTLA-4 Antigen 18 Bevacizumab 18 Radiosurgery 15 Paclitaxel 15 Carboplatin 14 encorafenib 13 binimetinib 13 Introns 13 talimogene laherparepvec 12 Radiotherapy 12 Interferon alpha-2 12 spartalizumab 11 cobimetinib 10 atezolizumab 10 sargramostim 9 peginterferon alfa-2b 9 montanide ISA 51 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × infigratinib × Clear all

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed

158 enrolled 40 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡